Diversified Enterprises LLC Grows Stake in Eli Lilly and Company $LLY

Diversified Enterprises LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 21.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,612 shares of the company’s stock after purchasing an additional 997 shares during the quarter. Diversified Enterprises LLC’s holdings in Eli Lilly and Company were worth $6,031,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company during the 4th quarter worth $25,000. Miller Global Investments LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth $33,000. Dorato Capital Management purchased a new position in Eli Lilly and Company during the 4th quarter worth $36,000. Vermillion & White Wealth Management Group LLC increased its holdings in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the period. Finally, 10Elms LLP increased its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion, adding AJ1-11095, a first‑in‑class Type II JAK2 inhibitor for myelofibrosis and polycythemia vera; the deal bolsters Lilly’s blood‑cancer pipeline and comes with Phase 1 data milestones later in 2026. Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion (Reuters)
• Positive Sentiment: April marks a continued buying spree for Lilly—this is at least the second oncology acquisition this month—signaling management’s deliberate push to diversify beyond GLP‑1s and build durable oncology revenues. Lilly Bets Again on Blood Cancer With Second Acquisition This Month (Yahoo)
• Neutral Sentiment: Jim Cramer flagged Lilly as a company that “will tell a good story” heading into earnings despite recent controversy, reflecting that broadcasters and some investors expect management to present positive near‑term messaging. Jim Cramer Says Eli Lilly “Will Tell a Good Story When It Reports” (Yahoo)
• Neutral Sentiment: Analysts and preview pieces highlight that Q1 earnings will be pivotal: GLP‑1 demand, pricing pressure, and Foundayo launch trends are key metrics to watch when Lilly reports. Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts? (Zacks)
• Neutral Sentiment: Broader sector M&A (e.g., Organon/Sun Pharma) is keeping investor focus on consolidation in pharma, which can support valuation multiples for active acquirers like Lilly. Organon Rides the Pharma M&A Wave With Sun Takeover (Yahoo)
• Negative Sentiment: Prescription data show Lilly’s oral Foundayo trailing Novo Nordisk’s Wegovy pill at a similar launch stage, raising concerns about market share, launch momentum and near‑term revenue upside for Lilly’s obesity franchise. GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival (Proactive)
• Negative Sentiment: Leerink Partners cut its price target on LLY from $1,296 to $1,058 while maintaining an outperform rating, a signal that at least some analysts see more near‑term downside or muted upside versus prior expectations. Leerink Partners adjusts PT on Eli Lilly (MarketScreener)

Eli Lilly and Company Trading Down 1.7%

Shares of NYSE:LLY opened at $868.59 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The business’s fifty day simple moving average is $955.40 and its 200-day simple moving average is $985.96. The company has a market capitalization of $820.66 billion, a PE ratio of 37.85, a P/E/G ratio of 1.05 and a beta of 0.51. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the previous year, the business earned $5.32 EPS. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 33.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of analyst reports. CICC Research lifted their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Guggenheim lifted their price target on Eli Lilly and Company from $1,163.00 to $1,183.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Royal Bank Of Canada initiated coverage on Eli Lilly and Company in a report on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price target on the stock. Finally, Zacks Research downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,216.52.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.